Johnson & Johnson’s (NYSE: JNJ) jab is the latest COVID-19 vaccine to be linked to rare cases of blood clots, prompting US health agencies to recommend pausing its use pending a review.
Shares in J&J were more than 2% lower in pre-market trading on Tuesday.
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have published a statement on the issue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze